Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10309217 | Schizophrenia Research | 2013 | 6 Pages |
Abstract
To compare the difference in body mass index (BMI), waist-to-hip ratio (WHR), and glucose and lipid metabolism parameters between drug-naïve, first-episode schizophrenia patients and healthy controls matched for age, ethnicity and gender, we conducted a test including BMI, WHR, and fasting glucose and lipid metabolism parameters in both 70 drug-naïve, first-episode schizophrenia patients, having not a single day of cumulative exposure to antipsychotic medications and 44 normal healthy controls at baseline. Student's t tests (two tailed) were conducted to examine between group differences. We found that drug-naïve first-episode schizophrenia patients had higher insulin, insulin resistance and C-peptide levels, and had lower total cholesterol (TC), high density lipoprotein cholesterol (HDL-c) and apolipoproteinA1 levels. Simultaneously, drug-naïve, first-episode schizophrenia patients show a potential tendency of WHR enlargement, although there were no statistically significant differences between groups (mean = 0.82, SD = 0.06, for the patients versus mean = 0.79, SD = 0.06, for the health subjects). These results suggest that drug-naïve, first-episode schizophrenia patients do differ from healthy controls in their fasting glycometabolism parameters and lipid profiles, including fasting plasma levels of insulin, C-peptide, TC, HDL-c, and apolipoproteinA1, and patients are more insulin resistant before the onset of antipsychotic medication treatment.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Xiaoli Wu, Zeping Huang, Renrong Wu, Zhiyong Zhong, Qinling Wei, Houliang Wang, Feici Diao, Jihui Wang, Liangrong Zheng, Jingping Zhao, Jinbei Zhang,